PURPOSE OF REVIEW: Inflammation has been shown to be an important factor in the development and progression of heart failure (HF)

 

Abstract

PURPOSE OF REVIEW: Inflammation has been shown to be an important factor in the development and progression of heart failure (HF), regardless of the etiology. There have been many studies that demonstrated roles of inflammatory biomarkers in diagnosis, prognosis of chronic and acute HF patients, and also markers of cardiotoxicity from chemotherapy. These cytokines are high-sensitivity C-reactive protein (hsCRP), myeloperoxidase (MPO), soluble growth stimulation expressed gene 2 (sST2), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFα), growth differentiation factor-15 (GDF-15), endothelin-1 (ET-1), and galectin-3. In this review, we discuss the past and present insights of those inflammatory biomarkers in order to gain more understanding in pathogenesis of HF, risk stratification of HF patients, and early detection of cardiotoxicity from cancer therapy.

RECENT FINDINGS: Many inflammatory cytokines have been shown to be associated with mortality of both chronic and acute HF patients, and some of them are able to track treatment responses, especially sST2 and galectin-3, which are the only two inflammatory biomarkers recommended to use in clinical setting by the recent standard HF guidelines, while some studies described ET-1 and MPO as potential predictors of cardiotoxicity from cancer drugs. The prognostic implications of inflammatory biomarkers in HF patients have been demonstrated more consistently in chronic than acute HF, with some suggestions of ET-1 and MPO in patients receiving chemotherapy. However, further studies are necessary for the use of inflammatory biomarkers in routine clinical practice.

PMID: 31916187 [PubMed - as supplied by publisher]

14:14

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

14:14

In reply to this message

pubmed: ctoall&ca or conall

Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats.

Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats.

Cancer Chemother Pharmacol. 2020 Jan 08;:

Authors: Sheibani M, Nezamoleslami S, Faghir-Ghanesefat H, Emami AH, Dehpour AR